Ignite Creation Date:
2025-12-24 @ 12:44 PM
Ignite Modification Date:
2026-02-23 @ 12:19 PM
Study NCT ID:
NCT00655161
Status:
COMPLETED
Last Update Posted:
2014-01-29
First Post:
2008-04-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
Sponsor:
GlobeImmune
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-04
Start Date Type:
None
Primary Completion Date:
2013-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-11
Completion Date Type:
ACTUAL
First Submit Date:
2008-04-02
First Submit QC Date:
None
Study First Post Date:
2008-04-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-01-28
Last Update Post Date:
2014-01-29
Last Update Post Date Type:
ESTIMATED